Abstract 1569P
Background
Today Breast cancer is the most commonly diagnosed cancer in women in India. Not only India has seen increasing incidence of breast cancer but also there is increase in mortality rate. While majority of patients in western nations are diagnosed in stage I or stage II, almost half of the patients in India present at a advanced stage. Though government authorities are doing their best to address this issue and community workers like Accredited Social health Activists and Auxillary Nurse Midwife have made significant impact, a large proportion of patients remain out of reach. Other methods need to be explored to be able to diagnose larger number of patients at an early stage.
Methods
A cross sectional study was conducted in south 24 paraganas, a rural district of West Bengal in India. 150 medical practioners practicing alternative medicine were enrolled in the study. Paper based case report forms were used and data was later entered into Excel sheets. Questionnaire recorded reasons for late presentation of patients, social, cultural and spiritual beliefs about the disease, economic impact, possible solution and what issues these practioners face in addressing these issues. Also these practioners were assessed as to how they examine and manage patients at their clinic.
Results
92% of practioners did not know how to examine breast lump and identify signs of malignancy 17% believed cancer is an incurable disease 26% were unaware of an oncologist and refer patients to general medical practioner 38% stated loss of daily wages and huge expenses in treatment were main reasons why patients delay treatment 11% stated stigma associated with surgery of breast and chemotherapy results in treatment avoidance.
Conclusions
Reasons for secondary delay in breast cancer diagnosis is multifactorial. Issues both among patients and practioners needs to be addressed. These practitioners are 1st line of contact for many of these patients and trusted by many. A network of these practioners can be built and they can be trained to examine and triage patients. Creation of referreal pathways to nearest oncology center, web or app based training and support programs, awareness about the disease and its management along with provision for financial assistance is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Netaji Subhash Chandra Bose Cancer Research Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10